Actively Recruiting
A First-in-Human Trial to Assess Safety and Effects of Subcutaneous GUB-UCN2 in Healthy Lean, Obese, and Type 2 Diabetes Participants
Led by Gubra A/S · Updated on 2026-09-10
188
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GUB-UCN2, a new drug administered by injection, in healthy lean people, individuals with obesity, and those living with Type 2 Diabetes. This study involves a treatment period of up to 16 weeks in selected groups and compares GUB-UCN2 given alone or alongside standard obesity treatments to a placebo. The trial is designed to assess how safe and tolerable the drug is, as well as how it behaves in the body. Participants will be randomly assigned to receive either the investigational drug GUB-UCN2 or a placebo. The study includes three parts Part 1 involves healthy lean participants, Part 2 includes obese male participants, and Part 3 involves participants with obesity or Type 2 Diabetes with varying body mass index ranges. All doses are given subcutaneously. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will undergo medical history reviews, safety assessments, and laboratory tests. Researchers will monitor treatment-emergent adverse events for up to 22 weeks and measure pharmacokinetics such as drug concentration over time. Participants will be followed through screening, treatment, and observation periods to evaluate safety and how the drug is processed in the body. The entire trial runs until December 2028.
CONDITIONS
Brief Title
A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
Research Team
S
Sr. Clinical Trial Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here